Major Rating Factors:
Poor long-term capitalization index (2.3 on a scale of 0 to 10) based on fair current risk adjusted capital (severe and moderate loss scenarios). Fair reserve development (3.6) as the level of reserves has at times been insufficient to cover claims. Deficiencies in the two year reserve development occurred in three of the previous five years and ranged between 20.4% and 612.1%. Good overall profitability index (5.8) despite operating losses during 2022. Return on equity has been good over the last five years, averaging 58.2%.
Other Rating Factors:
Good overall results on stability tests (5.7) despite weak risk adjusted capital in prior years and negative cash flow from operations for 2024. Stability strengths include excellent operational trends and good risk diversification. Superior liquidity (9.4) with ample operational cash flow and liquid investments.
Stability Factors:
C - Past results on our Risk-Adjusted Capital tests.
F - Negative cash flow.
T - Significant trends in critical asset, liability, income or expense items.
Principal Lines of Business:
Med mal (100.0%)
Licensed in:
NY
Principal Investments:
Investment grade bonds (83.6%), common stock (4.4%), cash (3.1%), preferred stock (1.4%), other (7.6%)
Corporate Info
Group Affiliation
None
Investment Rating
--
Company Address
77 Goodell Street
Buffalo, NY 14203
Buffalo, NY 14203
Phone Number
(646) 808-0600
NAIC Number
42544
Website
Largest Affiliates
No affiliate information available.